Related Experiment Video
Updated: May 24, 2026
Live Imaging of Drug Responses in the Tumor Microenvironment in Mouse Models of Breast Cancer
Published on: March 24, 2013
Noninvasive assessment of cancer response to therapy
Zhaozhong Han1, Allie Fu, Hailun Wang
1Department of Radiation Oncology, School of Medicine, Vanderbilt University, 1301 22nd Avenue South, B902 TVC, Nashville, Tennessee 37232, USA.
Abstract:
Rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. Although biopsies of cancer can be used to rapidly assess pharmacodynamic response, certain disease sites are less accessible to repeated biopsies. Here, we simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development and minimize the duration of treatment with ineffective regimens in cancer patients.
Insights
This study introduces a new peptide imaging agent for rapid, noninvasive cancer response assessment. This method helps identify effective cancer therapies early, improving patient outcomes and drug development.
Area of Science:
- Oncology
- Medical Imaging
- Pharmacodynamics
Background:
- Early assessment of cancer treatment efficacy is crucial for patient outcomes.
- Traditional methods like biopsies are invasive and not always feasible for all tumor sites.
- There is a need for noninvasive methods to monitor cancer response to therapy.
Purpose of the Study:
- To develop a rapid, noninvasive method for assessing cancer response to therapy.
- To identify a peptide that can differentiate between responding and nonresponding cancers.
- To enable simultaneous assessment of treatment response across all disease sites.
Main Methods:
- Peptide ligands were selected for their ability to distinguish responding from nonresponding cancers.
- The selected peptide (HVGGSSV) was conjugated to near-infrared imaging agents.
- The imaging agent was used to assess cancer response noninvasively.
Main Results:
- The HVGGSSV peptide successfully differentiated between responding and nonresponding cancers.
- Near-infrared imaging with the peptide allowed for rapid, noninvasive assessment of pharmacodynamic response.
- The method demonstrated the potential for simultaneous assessment across all disease sites.
Conclusions:
- This novel peptide-based imaging approach enables rapid, noninvasive assessment of cancer treatment response.
- This technology can accelerate cancer drug development by providing early efficacy data.
- It has the potential to minimize patient exposure to ineffective cancer therapies.
